Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study.

@article{Gollnick2010SystemicII,
  title={Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study.},
  author={Harald P. M. Gollnick and Ulrike Blume-Peytavi and E{\"o}rs Lāszlō Szab{\'o} and Kristina Meyer and Petra Hauptmann and Georg Popp and Michael Sebastian and Thomas Zwingers and Christoph Willers and Renate von der Weth},
  journal={Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG},
  year={2010},
  volume={8 7},
  pages={
          505-15
        }
}
BACKGROUND Systemic isotretinoin has been known for decades to be effective in the treatment of severe forms of rosacea, but it must be used off-label because of the lack of evidence-based data. PATIENTS AND METHODS 573 patients with rosacea subtype II and III received one of three different dosages of isotretinoin (0.1 mg, 0.3 mg, or 0.5 mg per kg body weight), doxycycline (100 mg daily for 14 days, then 50 mg daily) or placebo in a double-blinded, randomized way for 12 weeks in 35 German… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

Systematic review of rosacea treatments

  • EJ van Zuuren, AK Gupta, MD Gover, M Graber, S. Hollis
  • J Am Acad Dermatol
  • 2007

Similar Papers

Loading similar papers…